Curated News
By: NewsRamp Editorial Staff
April 09, 2025
Tonix Pharmaceuticals Collaborates with Makana Therapeutics for Xenotransplantation Research
TLDR
- Tonix Pharmaceuticals collaborates with Makana Therapeutics to develop human-compatible organs, advancing potential transplant solutions for organ failure.
- Research collaboration to evaluate anti-CD40L monoclonal antibody TNX-1500 with Makana's genetically engineered pigs for FDA investigational new drug application in xenotransplantation.
- Advancing treatments for organ failure through novel transplant solutions with improved human-compatible organs, aiming for compassionate use in xenotransplantation for a brighter medical future.
- Genetically engineered pigs without swine leukocyte antigen enhance human compatibility, offering hope for advanced medical solutions in organ failure and xenotransplantation.
Impact - Why it Matters
This news matters as it highlights a significant research collaboration between Tonix Pharmaceuticals and Makana Therapeutics to potentially revolutionize organ transplantation solutions, addressing organ failure through innovative approaches. The collaboration signifies a step towards developing compassionate use applications for xenotransplantation, paving the way for advanced treatments in the field of biopharmaceuticals and organ compatibility.
Summary
Tonix Pharmaceuticals (NASDAQ: TNXP) announced a research collaboration with Makana Therapeutics to evaluate TNX-1500, its anti-CD40L monoclonal antibody candidate, in preclinical studies alongside Makana’s human-compatible organs and cells. The studies aim to support a future investigational new drug application to the FDA for compassionate use in xenotransplantation. Makana’s genetically engineered pigs, designed without swine leukocyte antigen, have demonstrated improved human compatibility, positioning both companies to advance potential treatments for organ failure through novel transplant solutions.
Source Statement
This curated news summary relied on this press release disributed by InvestorBrandNetwork (IBN). Read the source press release here, Tonix Pharmaceuticals Collaborates with Makana Therapeutics for Xenotransplantation Research
